Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1357250

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1357250

Metabolism Assays Market by Product, Technology, Application (Diagnostics, Research), End User, & Region - Global Forecast to 2028

PUBLISHED:
PAGES: 188 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

The metabolism assays market is projected to reach USD 2.1 billion by 2028 from USD 1.4 billion in 2023, at a CAGR of 7.8% during the forecast period. The growth of this market is majorly driven by the promotion of metabolic research and funding by the government, the growing use of metabolism assays in fitness and sports industry, and an increase in the awareness of early diagnosis. However, issues related high cost of metabolism assays restrain the growth of this market.

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredUSD
SegmentsProduct,Technology,Application,End User,Region
Regions coveredNorth America, Europe, APAC, RoW

"The assay kits & reagents segment accounted for the highest market share in the metabolism assays market, by product, during the forecast period."

Based on the product segment, the metabolism assays market is classified into instruments & analyzers and assay kits & reagents. In 2022, the assay kits & reagents segment dominated the products market. This segment is also estimated to grow at the highest CAGR during the forecast period. The large share is due to their integration with technologies, such as wearable devices and wide use in diagnostics as it is the major application.

"Pharmaceutical & Biotechnology Companies and CROs & Academic Research Institutes accounted for the highest CAGR during the forecast period."

Based on end users, the metabolism assays market is segmented into hospitals, diagnostic laboratories, and pharmaceutical & biotechnology companies and CROs & academic research institutes. The pharmaceutical & biotechnology companies and CROs & academic research institutes segment dominated the metabolism assays market in 2022. The diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period. The large share of this segment can be attributed to increasing R&D investments by pharmaceutical & biotechnology companies on metabolic research.

"The North America segment accounted for the highest market share in the metabolism assays market, by region, during the forecast period."

Based on the region, the global metabolism assays market is categorized into North America, Europe, Asia Pacific, and Rest of the World. During the forecast period North America is expected to witness a high market share. The presence of robust pharma & biotech industries who are involved in drug discover, toxicity testing & development and the increasing target disease population are supporting the growth of the metabolism assays market. However, Asia Pacific is expected to register highest CAGR during the forecast period.

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Company Type: Tier 1 (30%), Tier 2 (48%), and Tier 3 (22%)
  • By Designation: C-level (28%), Director-level (33%), and Others (39%)
  • By Region: North America (21%), Asia-Pacific (34%), Europe (30%), and RoW (15%)

Prominent companies include Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), Agilent Technologies Inc. (US), Kaneka Eurogentec S.A. (Belgium), Sartorius AG (Germany), Promega Corporation (US), Elabscience Biotechnology Inc. (US), RayBiotech Life Inc. (US), BMG LABTECH (Germany), BIOTREND ChemiKalien GmbH (Germany), 3H Biomedical AB (Sweden), BioAssay Systems (US), EMELCA Bioscience (Netherlands), Creative Bioarray (US), Tempo Bioscience, Inc (US), Ncardia (Netherlands), NOVOCIB (France), Eton Bioscience Inc. (US), Cayman Chemical Company (US), Enzo Lifesciences, Inc. (US), and Abnova Corporation (Taiwan).

Research Coverage

This research report categorizes the metabolism assays market by product, technology, application, end-user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the metabolism assays market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, services; key strategies; Contracts, partnerships, and agreements. New product & service launches, mergers and acquisitions, and recent developments associated with the metabolism assays market. Competitive analysis of upcoming startups in the metabolism assays market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall metabolism assays market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the metabolism assays market
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the metabolism assays market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the metabolism assays market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the metabolism assays market
  • Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like Merck KGaA (Germany), Thermo Fisher (US), Abcam Plc. (UK), and Agilent Technologies Inc. (US), among others in the metabolism assays market strategies.
Product Code: MD 8811

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • TABLE 1 INCLUSIONS AND EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 LIMITATIONS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 METABOLISM ASSAYS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
    • TABLE 2 KEY DATA FROM PRIMARY SOURCES
    • FIGURE 2 KEY INDUSTRY INSIGHTS
      • 2.1.2.1 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 BOTTOM-UP APPROACH: REVENUE-BASED APPROACH
    • 2.2.1 GROWTH FORECAST
    • 2.2.2 CAGR PROJECTIONS
    • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.3 TOP-DOWN APPROACH
    • FIGURE 7 METABOLISM ASSAYS MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE/RANKING ANALYSIS
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ASSESSMENT
  • 2.7 IMPACT OF RECESSION

3 EXECUTIVE SUMMARY

    • FIGURE 9 METABOLISM ASSAYS MARKET, BY PRODUCT, 2023 VS. 2028 (USD BILLION)
    • FIGURE 10 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD BILLION)
    • FIGURE 11 METABOLISM ASSAYS MARKET, BY APPLICATION, 2023 VS. 2028 (USD BILLION)
    • FIGURE 12 METABOLISM ASSAYS MARKET, BY END USER, 2023 VS. 2028 (USD BILLION)
    • FIGURE 13 REGIONAL SNAPSHOT OF METABOLISM ASSAYS MARKET

4 PREMIUM INSIGHTS

  • 4.1 METABOLISM ASSAYS MARKET OVERVIEW
    • FIGURE 14 INCREASED PREVALENCE OF OBESITY AND DIABETES TO DRIVE METABOLISM ASSAYS MARKET
  • 4.2 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT (2022)
    • FIGURE 15 ASSAY KITS & REAGENTS ACCOUNTED FOR LARGEST SHARE IN 2022
  • 4.3 REGIONAL GROWTH OPPORTUNITIES IN METABOLISM ASSAYS MARKET
    • FIGURE 16 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • 4.4 METABOLISM ASSAYS MARKET: REGIONAL MIX
    • FIGURE 17 ASIA PACIFIC MARKET TO WITNESS FASTEST GROWTH DURING FORECAST PERIOD
  • 4.5 METABOLISM ASSAYS MARKET: DEVELOPED VS. EMERGING ECONOMIES
    • FIGURE 18 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN METABOLISM ASSAYS MARKET
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing funding and investments in metabolic research
      • 5.2.1.2 Drug discovery and development
      • 5.2.1.3 Rise in prevalence of chronic diseases
      • 5.2.1.4 Increased use of metabolism assays in fitness and sports
      • 5.2.1.5 Growing demand for personalized medicines
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of metabolism assay analyzers
      • 5.2.2.2 Presence of alternative methods and techniques
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Integration with wearable devices
      • 5.2.3.2 Growing life science research in emerging economies
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Complexity of assay development
  • 5.3 PRICING ANALYSIS
    • TABLE 3 AVERAGE SELLING PRICE OF PRODUCT, BY KEY PLAYERS
  • 5.4 PATENT ANALYSIS
    • FIGURE 20 PATENT ANALYSIS FOR METABOLISM ASSAYS (JANUARY 2013-DECEMBER 2022)
    • 5.4.1 LIST OF KEY PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASES
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 22 METABOLISM ASSAYS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • FIGURE 23 METABOLISM ASSAYS MARKET: ECOSYSTEM ANALYSIS
    • 5.7.1 METABOLISM ASSAYS MARKET: ROLE IN ECOSYSTEM
    • FIGURE 24 KEY PLAYERS IN METABOLISM ASSAYS MARKET
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 PORTER'S FIVE FORCES ANALYSIS: METABOLISM ASSAYS MARKET
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF SUPPLIERS
    • 5.8.4 BARGAINING POWER OF BUYERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 NORTH AMERICA
      • 5.9.1.1 US
    • TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION
      • 5.9.1.2 Canada
    • TABLE 6 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
    • 5.9.2 EUROPE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 Japan
    • TABLE 7 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
      • 5.9.3.2 China
    • TABLE 8 CHINA: CLASSIFICATION OF MEDICAL DEVICES
      • 5.9.3.3 India
  • 5.10 TRADE ANALYSIS
    • TABLE 9 IMPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018-2022 (USD MILLION)
    • TABLE 10 EXPORT DATA FOR DIAGNOSTIC OR LABORATORY REAGENTS ON A BACKING, PREPARED DIAGNOSTIC OR LABORATORY REAGENTS WHETHER OR NOT ON A BACKING, AND CERTIFIED REFERENCE MATERIALS, BY COUNTRY, 2018-2022 (USD MILLION)
  • 5.11 TECHNOLOGY ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS IN 2023-2024
    • TABLE 11 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, 2023-2024
  • 5.13 TRENDS/DISRUPTIONS IMPACTING BUSINESSES
    • 5.13.1 REVENUE SHIFT IN METABOLISM ASSAYS
  • 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
    • TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF METABOLISM ASSAYS
    • 5.14.2 BUYING CRITERIA
    • FIGURE 26 KEY BUYING CRITERIA FOR METABOLISM ASSAYS
    • TABLE 13 KEY BUYING CRITERIA FOR METABOLISM ASSAYS

6 METABOLISM ASSAYS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 14 METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
  • 6.2 ASSAY KITS & REAGENTS
    • 6.2.1 COST-EFFECTIVENESS TO INCREASE ADOPTION IN DRUG DISCOVERY
    • TABLE 15 ASSAY KITS AVAILABLE IN MARKET
    • TABLE 16 METABOLISM ASSAYS MARKET: ASSAY KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS & ANALYZERS
    • 6.3.1 AUTOMATION IN INSTRUMENTS, ALONG WITH ADOPTION OF SOFTWARE, TO DRIVE SEGMENTAL GROWTH
    • TABLE 17 INSTRUMENTS & ANALYZERS AVAILABLE IN MARKET
    • TABLE 18 METABOLISM ASSAYS MARKET: INSTRUMENTS & ANALYZERS, BY REGION, 2021-2028 (USD MILLION)

7 METABOLISM ASSAYS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 19 METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
  • 7.2 COLORIMETRY
    • 7.2.1 COST-EFFECTIVENESS TO DRIVE MARKET
    • TABLE 20 METABOLISM ASSAYS MARKET FOR COLORIMETRY, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 FLUORIMETRY
    • 7.3.1 HIGH SENSITIVITY AND SPECIFICITY TO DRIVE MARKET
    • TABLE 21 METABOLISM ASSAYS MARKET FOR FLUORIMETRY, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 SPECTROMETRY
    • 7.4.1 INCREASED IMPORTANCE IN RESEARCH AND CLINICAL DIAGNOSTICS TO DRIVE MARKET
    • TABLE 22 METABOLISM ASSAYS MARKET FOR SPECTROMETRY, BY REGION, 2021-2028 (USD MILLION)

8 METABOLISM ASSAYS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 23 METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 8.2 DIAGNOSTICS
    • 8.2.1 GROWING PREVALENCE OF METABOLIC AND CHRONIC DISEASES TO DRIVE MARKET
    • TABLE 24 DIAGNOSTICS: METABOLISM ASSAYS MARKET, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 25 METABOLISM ASSAYS MARKET FOR DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.2 DIABETES
    • TABLE 26 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR DIABETES, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.3 OBESITY
    • TABLE 27 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OBESITY, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.4 CANCER
    • TABLE 28 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.5 CARDIOVASCULAR DISEASES
    • TABLE 29 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021-2028 (USD MILLION)
    • 8.2.6 OTHER DIAGNOSTICS
    • TABLE 30 DIAGNOSTICS: METABOLISM ASSAYS MARKET FOR OTHER DIAGNOSTICS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 RESEARCH
    • 8.3.1 INCREASE IN AWARENESS OF METABOLISM ASSAY IN DISEASE RESEARCH
    • TABLE 31 RESEARCH: METABOLISM ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)

9 METABOLISM ASSAYS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 32 METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 HOSPITALS
    • 9.2.1 AFFORDABILITY AND CONVENIENCE TO DRIVE SEGMENT
    • TABLE 33 METABOLISM ASSAYS MARKET FOR HOSPITALS, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 DIAGNOSTIC LABORATORIES
    • 9.3.1 INCREASED OUTSOURCING OF LABORATORY DIAGNOSES FOR REDUCTION IN COSTS TO DRIVE MARKET
    • TABLE 34 METABOLISM ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES
    • 9.4.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
    • TABLE 35 METABOLISM ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS & ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)

10 METABOLISM ASSAYS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 36 METABOLISM ASSAYS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 27 NORTH AMERICA: METABOLISM ASSAYS MARKET SNAPSHOT
    • TABLE 37 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 38 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 39 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 40 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 41 NORTH AMERICA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 High rate of drug discovery and toxicity testing to drive market
    • TABLE 42 US: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 43 US: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 44 US: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 45 US: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 High prevalence of obesity to fuel market growth
    • TABLE 46 CANADA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 47 CANADA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 48 CANADA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 49 CANADA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 50 EUROPE: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 51 EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 52 EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 53 EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 54 EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Growth of pharmaceutical companies to drive market
    • TABLE 55 GERMANY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 56 GERMANY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 57 GERMANY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 58 GERMANY: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Growing cancer research funding to drive market
    • TABLE 59 UK: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 60 UK: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 61 UK: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 62 UK: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising obese population and prevalence of metabolic disorders to drive market
    • TABLE 63 FRANCE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 64 FRANCE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 65 FRANCE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 66 FRANCE: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Increasing prevalence of aging population and diabetes to drive market
    • TABLE 67 SPAIN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 68 SPAIN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 69 SPAIN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 70 SPAIN: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 ITALY
      • 10.3.6.1 Growth of pharmaceutical industry to boost market
    • TABLE 71 ITALY: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 72 ITALY: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 73 ITALY: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 74 ITALY: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 75 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 76 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 77 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 78 REST OF EUROPE: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: METABOLISM ASSAYS MARKET SNAPSHOT
    • 10.4.1 RECESSION IMPACT
    • TABLE 79 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Government initiatives to drive market
    • TABLE 84 JAPAN: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 85 JAPAN: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 86 JAPAN: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 87 JAPAN: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 CHINA
      • 10.4.3.1 Increasing health awareness to drive demand
    • TABLE 88 CHINA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 89 CHINA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 90 CHINA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 91 CHINA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Prevalence of chronic diseases to fuel demand
    • TABLE 92 INDIA: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 93 INDIA: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 94 INDIA: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 95 INDIA: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 96 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 97 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 98 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 99 REST OF ASIA PACIFIC: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 REST OF THE WORLD
    • 10.5.1 RECESSION IMPACT
    • TABLE 100 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY PRODUCT, 2021-2028 (USD MILLION)
    • TABLE 101 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION)
    • TABLE 102 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 103 REST OF THE WORLD: METABOLISM ASSAYS MARKET, BY END USER, 2021-2028 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 104 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN METABOLISM ASSAYS MARKET
  • 11.4 MARKET RANKING ANALYSIS
    • FIGURE 30 METABOLISM ASSAYS MARKET RANKING ANALYSIS, BY KEY PLAYER (2022)
  • 11.5 COMPANY EVALUATION QUADRANT (2022)
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 31 METABOLISM ASSAYS MARKET: COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022
  • 11.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2022)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 32 METABOLISM ASSAY MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022
  • 11.7 COMPETITIVE BENCHMARKING
    • TABLE 105 METABOLISM ASSAYS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
    • TABLE 106 PRODUCT FOOTPRINT OF KEY PLAYERS
    • TABLE 107 REGIONAL FOOTPRINT OF KEY PLAYERS
    • TABLE 108 METABOLISM ASSAYS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES
    • TABLE 109 PRODUCT LAUNCHES, JANUARY 2020-AUGUST 2023
    • 11.8.2 DEALS
    • TABLE 110 DEALS, JANUARY 2020-AUGUST 2023
    • 11.8.3 OTHER DEVELOPMENTS
    • TABLE 111 OTHER DEVELOPMENTS, JANUARY 2020-AUGUST 2023

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 THERMO FISHER SCIENTIFIC INC.
    • TABLE 112 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.2 MERCK KGAA
    • TABLE 113 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022)
    • 12.1.3 ABCAM PLC.
    • TABLE 114 ABCAM PLC.: BUSINESS OVERVIEW
    • FIGURE 35 ABCAM PLC.: COMPANY SNAPSHOT (2022)
    • TABLE 115 ABCAM PLC.: DEALS
    • 12.1.4 AGILENT TECHNOLOGIES INC.
    • TABLE 116 AGILENT TECHNOLOGIES INC.: BUSINESS OVERVIEW
    • FIGURE 36 AGILENT TECHNOLOGIES INC.: COMPANY SNAPSHOT (2022)
    • TABLE 117 AGILENT TECHNOLOGIES INC.: PRODUCT LAUNCHES
    • 12.1.5 KANEKA EUROGENTEC S.A.
    • TABLE 118 KANEKA EUROGENTEC S.A.: BUSINESS OVERVIEW
    • FIGURE 37 KANEKA EUROGENTEC S.A.: COMPANY SNAPSHOT (2022)
    • 12.1.6 SARTORIUS AG
    • TABLE 119 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 38 SARTORIUS AG: COMPANY SNAPSHOT (2022)
    • TABLE 120 SARTORIUS AG: PRODUCT LAUNCHES
    • 12.1.7 PROMEGA CORPORATION
    • TABLE 121 PROMEGA CORPORATION: BUSINESS OVERVIEW
    • 12.1.8 ELABSCIENCE BIOTECHNOLOGY INC.
    • TABLE 122 ELABSCIENCE BIOTECHNOLOGY INC.: BUSINESS OVERVIEW
    • 12.1.9 RAYBIOTECH LIFE, INC.
    • TABLE 123 RAYBIOTECH LIFE, INC.: BUSINESS OVERVIEW
    • 12.1.10 BMG LABTECH
    • TABLE 124 BMG LABTECH: BUSINESS OVERVIEW
    • TABLE 125 BMG LABTECH: PRODUCT LAUNCHES
    • 12.1.11 BIOTREND CHEMIKALIEN GMBH
    • TABLE 126 BIOTREND CHEMIKALIEN GMBH: BUSINESS OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 3H BIOMEDICAL AB
    • 12.2.2 BIOASSAY SYSTEMS
    • 12.2.3 EMELCA BIOSCIENCE
    • 12.2.4 CREATIVE BIOARRAY
    • 12.2.5 TEMPO BIOSCIENCE, INC.
    • 12.2.6 NCARDIA
    • 12.2.7 NOVOCIB
    • 12.2.8 ETON BIOSCIENCE, INC.
    • 12.2.9 CAYMAN CHEMICAL COMPANY
    • 12.2.10 ENZO LIFE SCIENCES, INC.
    • 12.2.11 ABNOVA CORPORATION
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!